vs
NEOGENOMICS INC（NEO）与UL Solutions Inc.（ULS）财务数据对比。点击上方公司名可切换其他公司
UL Solutions Inc.的季度营收约是NEOGENOMICS INC的4.1倍（$789.0M vs $190.2M）。NEOGENOMICS INC同比增速更快（10.6% vs 6.8%）。UL Solutions Inc.自由现金流更多（$86.0M vs $-6.5M）。过去两年NEOGENOMICS INC的营收复合增速更高（10.3% vs 8.5%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
UL是总部位于美国伊利诺伊州诺斯布鲁克的全球私营安全领域企业，旗下设有三大机构：UL研究院、UL标准与倡议部门以及UL Solutions，为全球各行业客户提供标准制定、检测认证、风险管控等专业安全服务，保障产品与运营的合规性与安全性，助力企业可持续发展。
NEO vs ULS — 直观对比
营收规模更大
ULS
是对方的4.1倍
$190.2M
营收增速更快
NEO
高出3.8%
6.8%
自由现金流更多
ULS
多$92.5M
$-6.5M
两年增速更快
NEO
近两年复合增速
8.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $190.2M | $789.0M |
| 净利润 | — | $67.0M |
| 毛利率 | 43.8% | 49.7% |
| 营业利润率 | -7.1% | 15.0% |
| 净利率 | — | 8.5% |
| 营收同比 | 10.6% | 6.8% |
| 净利润同比 | — | -17.3% |
| 每股收益（稀释后） | — | $0.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOULS
| Q4 25 | $190.2M | $789.0M | ||
| Q3 25 | $187.8M | $783.0M | ||
| Q2 25 | $181.3M | $776.0M | ||
| Q1 25 | $168.0M | $705.0M | ||
| Q4 24 | $172.0M | $739.0M | ||
| Q3 24 | $167.8M | $731.0M | ||
| Q2 24 | $164.5M | $730.0M | ||
| Q1 24 | $156.2M | $670.0M |
净利润NEOULS
| Q4 25 | — | $67.0M | ||
| Q3 25 | $-27.1M | $100.0M | ||
| Q2 25 | $-45.1M | $91.0M | ||
| Q1 25 | $-25.9M | $67.0M | ||
| Q4 24 | — | $81.0M | ||
| Q3 24 | $-17.7M | $88.0M | ||
| Q2 24 | $-18.6M | $101.0M | ||
| Q1 24 | $-27.1M | $56.0M |
毛利率NEOULS
| Q4 25 | 43.8% | 49.7% | ||
| Q3 25 | 42.8% | 50.3% | ||
| Q2 25 | 42.6% | 49.4% | ||
| Q1 25 | 43.6% | 48.4% | ||
| Q4 24 | 44.9% | 47.4% | ||
| Q3 24 | 44.6% | 49.0% | ||
| Q2 24 | 44.1% | 50.1% | ||
| Q1 24 | 41.9% | 47.6% |
营业利润率NEOULS
| Q4 25 | -7.1% | 15.0% | ||
| Q3 25 | -14.4% | 19.9% | ||
| Q2 25 | -26.3% | 17.9% | ||
| Q1 25 | -16.6% | 15.5% | ||
| Q4 24 | -10.7% | 15.6% | ||
| Q3 24 | -12.6% | 17.8% | ||
| Q2 24 | -13.3% | 17.3% | ||
| Q1 24 | -19.6% | 13.6% |
净利率NEOULS
| Q4 25 | — | 8.5% | ||
| Q3 25 | -14.4% | 12.8% | ||
| Q2 25 | -24.9% | 11.7% | ||
| Q1 25 | -15.4% | 9.5% | ||
| Q4 24 | — | 11.0% | ||
| Q3 24 | -10.5% | 12.0% | ||
| Q2 24 | -11.3% | 13.8% | ||
| Q1 24 | -17.3% | 8.4% |
每股收益（稀释后）NEOULS
| Q4 25 | — | $0.33 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | — | $0.45 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $0.44 | ||
| Q2 24 | — | $0.50 | ||
| Q1 24 | — | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $159.6M | $295.0M |
| 总债务越低越好 | $341.9M | $491.0M |
| 股东权益账面价值 | $836.6M | $1.3B |
| 总资产 | $1.4B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.41× | 0.39× |
8季度趋势，按日历期对齐
现金及短期投资NEOULS
| Q4 25 | $159.6M | $295.0M | ||
| Q3 25 | $164.1M | $255.0M | ||
| Q2 25 | $154.7M | $272.0M | ||
| Q1 25 | $346.2M | $267.0M | ||
| Q4 24 | $367.0M | $298.0M | ||
| Q3 24 | $362.0M | $327.0M | ||
| Q2 24 | $355.1M | $295.0M | ||
| Q1 24 | $331.9M | $344.0M |
总债务NEOULS
| Q4 25 | $341.9M | $491.0M | ||
| Q3 25 | — | $544.0M | ||
| Q2 25 | — | $608.0M | ||
| Q1 25 | — | $653.0M | ||
| Q4 24 | $541.1M | $742.0M | ||
| Q3 24 | — | $797.0M | ||
| Q2 24 | — | $810.0M | ||
| Q1 24 | — | $879.0M |
股东权益NEOULS
| Q4 25 | $836.6M | $1.3B | ||
| Q3 25 | $838.3M | $1.2B | ||
| Q2 25 | $854.0M | $1.1B | ||
| Q1 25 | $888.3M | $970.0M | ||
| Q4 24 | $902.3M | $904.0M | ||
| Q3 24 | $908.2M | $872.0M | ||
| Q2 24 | $915.9M | $769.0M | ||
| Q1 24 | $923.4M | $671.0M |
总资产NEOULS
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.4B | $2.9B | ||
| Q1 25 | $1.6B | $2.9B | ||
| Q4 24 | $1.6B | $2.8B | ||
| Q3 24 | $1.6B | $2.9B | ||
| Q2 24 | $1.6B | $2.7B | ||
| Q1 24 | $1.6B | $2.8B |
负债/权益比NEOULS
| Q4 25 | 0.41× | 0.39× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.56× | ||
| Q1 25 | — | 0.67× | ||
| Q4 24 | 0.60× | 0.82× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.31× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3M | $144.0M |
| 自由现金流经营现金流 - 资本支出 | $-6.5M | $86.0M |
| 自由现金流率自由现金流/营收 | -3.4% | 10.9% |
| 资本支出强度资本支出/营收 | 4.1% | 7.4% |
| 现金转化率经营现金流/净利润 | — | 2.15× |
| 过去12个月自由现金流最近4个季度 | $-21.8M | $403.0M |
8季度趋势，按日历期对齐
经营现金流NEOULS
| Q4 25 | $1.3M | $144.0M | ||
| Q3 25 | $8.9M | $155.0M | ||
| Q2 25 | $20.3M | $147.0M | ||
| Q1 25 | $-25.3M | $154.0M | ||
| Q4 24 | $9.8M | $130.0M | ||
| Q3 24 | $9.2M | $150.0M | ||
| Q2 24 | $13.9M | $103.0M | ||
| Q1 24 | $-25.9M | $141.0M |
自由现金流NEOULS
| Q4 25 | $-6.5M | $86.0M | ||
| Q3 25 | $570.0K | $109.0M | ||
| Q2 25 | $14.0M | $105.0M | ||
| Q1 25 | $-29.8M | $103.0M | ||
| Q4 24 | $-1.8M | $72.0M | ||
| Q3 24 | $-1.6M | $84.0M | ||
| Q2 24 | $814.0K | $47.0M | ||
| Q1 24 | $-31.5M | $84.0M |
自由现金流率NEOULS
| Q4 25 | -3.4% | 10.9% | ||
| Q3 25 | 0.3% | 13.9% | ||
| Q2 25 | 7.7% | 13.5% | ||
| Q1 25 | -17.8% | 14.6% | ||
| Q4 24 | -1.0% | 9.7% | ||
| Q3 24 | -0.9% | 11.5% | ||
| Q2 24 | 0.5% | 6.4% | ||
| Q1 24 | -20.2% | 12.5% |
资本支出强度NEOULS
| Q4 25 | 4.1% | 7.4% | ||
| Q3 25 | 4.4% | 5.9% | ||
| Q2 25 | 3.5% | 5.4% | ||
| Q1 25 | 2.7% | 7.2% | ||
| Q4 24 | 6.7% | 7.8% | ||
| Q3 24 | 6.4% | 9.0% | ||
| Q2 24 | 8.0% | 7.7% | ||
| Q1 24 | 3.6% | 8.5% |
现金转化率NEOULS
| Q4 25 | — | 2.15× | ||
| Q3 25 | — | 1.55× | ||
| Q2 25 | — | 1.62× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 1.60× | ||
| Q3 24 | — | 1.70× | ||
| Q2 24 | — | 1.02× | ||
| Q1 24 | — | 2.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEO
| Client Direct Billing | $133.4M | 70% |
| Commercial Insurance | $31.4M | 17% |
| Medicare And Other Governmental | $25.4M | 13% |
ULS
| Industrial | $352.0M | 45% |
| Ongoing Certification Services | $259.0M | 33% |
| Software And Advisory | $102.0M | 13% |
| Software | $75.0M | 10% |
